Salivary Gland Infection Therapeutics Market Size | 2032

Report Description

Salivary Gland Infection Therapeutics Market Outlook 2032

The global salivary gland infection therapeutics market size was USD 2.71 Billion in 2023 and is projected to reach USD 4.46 Billion by 2032, expanding at a CAGR of 5.7% during 2024–2032. The market growth is attributed to the ­­ increasing demand for effective therapeutics to address health concerns.

Increasing awareness about oral health and advancements in medical technology resulted in high adoption of salivary gland infection therapeutics, which further propels the market. Therapeutics for salivary gland infections are heavily used in dental clinics, hospitals, and specialty healthcare centers. Additionally, the increasing instances of salivary gland infections and the growing consumer base for effective treatments for salivary gland infections, including aged individuals seeking preventive care for their gland infections, boosts the market.

• According to the report published by the National Library of Medicine in September 2022, salivary gland diseases were predominantly observed in women within the age group of 51-60 years.
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) on the Salivary Gland Infection Therapeutics Market

The use of artificial intelligence is likely to boost the salivary gland infection therapeutics market. AI algorithms leverage machine learning techniques to identify patterns in patient data for personalized treatment approaches. Additionally, AI-driven predictive analytics models forecast possibilities of disease and treatment outcomes to improve patient outcomes.

Salivary Gland Infection Therapeutics Market Dynamics

Get Free Sample Report

Major Drivers

Increasing prevalence of salivary gland infections is expected to drive the market in the coming years. Factors such as poor oral hygiene, autoimmune diseases, and viral infections contribute to the growing prevalence of salivary gland infections. For instance, according to the report published by the National Library of Medicine in January 2022, salivary gland pathologies were diagnosed in 230,589 patients over 10 years in Poland. Moreover, the growing number of elderly population suffering from these types of diseases boosts the market.

Existing Restraints

Limited availability of specific treatment options is anticipated to hinder the market during the forecast period. Despite advancements in medical science, only a few targeted therapeutics are available for salivary gland infection. Moreover, the high cost associated with the treatment of salivary gland infections hinders the market.

Emerging Opportunities

Rising investments in research and development (R&D) activities are expected to create immense opportunities for the players competing in the market. Pharmaceutical companies and research institutions are focusing on developing novel treatment options for salivary gland infections. Moreover, advancements in technology, such as targeted drug delivery systems and personalized medicine, offer effective and efficient therapeutics for salivary gland infections, which propel the market.

Scope of the Salivary Gland Infection Therapeutics Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Salivary Gland Infection Therapeutics Market Segment Insights

Infection Segment Analysis

Based on infection, the global market is divided into submandibular glands, sublingual glands, parotid glands, and others. The parotid glands segment is expected to expand at a significant growth rate in the coming years, due to the high prevalence of infections affecting the parotid glands.

Parotid glands are the major salivary glands located near the ear, which makes them susceptible to infections, as they are in proximity to potential sources of pathogens. Moreover, the advancements in ultrasound and sialography diagnostic techniques for accurate identification and facilitating targeted parotid treatment strategies boost the segment.

Get Free Sample Report

Drug Class Segment Analysis

On the basis of drug class, the global market is segregated into NSAIDs, antibiotics, and others. The antibiotics segment held a large market share in 2023, due to the widespread use of antibiotics in the treatment of salivary gland infections. Antibiotics are commonly prescribed as first-line therapy for bacterial infections, such as bacterial sialadenitis, affecting the salivary glands. Moreover, the availability of a wide range of antibiotics with varying spectra of activity boosts their demand, thereby fueling the segment.

The NSAIDs segment is anticipated to expand at a substantial CAGR during the forecast period, as they are commonly used as adjunctive therapy to antibiotics in the treatment of salivary gland infections. They are particularly beneficial to alleviate pain, inflammation, and swelling associated with the condition. Furthermore, the favorable safety profile of NSAIDs, which is suitable for long-term use in chronic or recurrent salivary gland infections boosts the segment.

Distribution Channel Segment Analysis

Based on distribution channel, the salivary gland infection therapeutics market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the market in terms of revenue generation in 2023, owing to the widespread availability of salivary gland therapeutics through hospital pharmacies.

Hospital pharmacies ensure timely access to specialized medications for patients undergoing treatment for salivary gland disorders. Moreover, the presence of skilled pharmacists in these pharmacies for comprehensive patient counseling about medication fuels the segment.

The online pharmacies segment is projected to register a robust growth rate during the assessment years. Online pharmacies allow patients to order salivary gland medications from the comfort of their homes directly to their doorstep. Moreover, online pharmacies provide comprehensive medication information and personalized support services to enhance treatment outcomes, which further fuels the segment.

Get Free Sample Report

End-user Segment Analysis

On the basis of end-user, the market is divided into clinical laboratories, hospitals, ambulatory surgical centers, and others. The hospitals segment accounted for a major share of the market in 2023, due to widespread adoption of salivary gland therapeutics in hospital settings. Hospitals serve as primary hubs for the diagnosis and treatment of various diseases and conditions. Moreover, the availability of skilled healthcare professionals ensuring the safe and effective administration of these therapeutics propels the segment.

Regional Outlook

In terms of region, the global salivary gland infection therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to its well-established healthcare infrastructure and extensive research and development activities for novel therapeutics. Advanced diagnostic capabilities in the region allow for timely identification and treatment of salivary gland infections. Moreover, the high prevalence of salivary gland infections and cancer patients boosts the market in this region.

• As per the report published by the American Cancer Society on March 18, 2023, salivary gland cancers account for 6% to 8% of all head and neck cancers in the US. Additionally, approximately 2,000 to 2,500 cases are reported in the US each year.

The market in Asia Pacific is projected to grow at a significant pace in the coming years, owing to the presence of a large patient pool for salivary gland infection. Poor oral hygiene practices and inadequate access to healthcare facilities in underdeveloped countries in the region contribute to the high prevalence of these infections. Furthermore, the rapidly growing population suffering from gland infections and diseases fuels the market.

Get Free Sample Report